Advertisement: Hewitsons mid banner
Advertisement: Mogrify mid banner
RealVNC mid banner careers
Advertisement: Cambridge Network mid banner
Advertisement: EBCam mid banner
Advertisement: Kao Data Centre mid banner
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: EY Mid banner
Advertisement: RSM
Advertisement: Howard Group mid banner
Advertisement mid banner S-Tech 1
Advertisement: Simpsons Creative
Advertisement – Charles Stanley mid banner
Mid banner advertisement: BDO
1 December, 2020 - 09:31 By Tony Quested

Sosei Heptares wins $380m-plus deal with Wall Street group

Sosei Group Corporation, which steers gamechanging research from its Cambridge UK base, has clinched a minimum of $380 million in revenues from a collaboration with Wall Street quoted Biohaven Pharmaceutical Holding Company Ltd. 

Connecticut company Biohaven will receive exclusive global rights to develop, manufacture and commercialise a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. 

The portfolio includes the lead candidate HTL0022562, which has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials.

In return, Sosei Heptares will receive an upfront payment of $10m in the form of cash consideration and Biohaven common shares, research funding, and is eligible to receive additional development, regulatory and commercialisation milestone payments of up to $370m. 

Sosei Heptares will also be eligible to receive tiered royalties on net sales of products resulting from the collaboration.

Vlad Coric, CEO of Biohaven, said: “We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery. 

“Biohaven launched NURTECä ODT (rimegepant), our lead CGRP receptor antagonist oral small molecule for the acute treatment of migraine in March of this year in the US and have submitted an sNDA for the preventive treatment of migraine with an expected PDUFA in the second quarter of 2021. 

“We have also advanced zavegepant, our intra-nasal CGRP receptor antagonist, successfully through its first pivotal trial, also for the acute treatment of migraine. 

“We are now committed to pursuing other CGRP-mediated diseases through advancing novel investigational agents such as HTL0022562 into human studies.”

Shinichi Tamura, chairman, president and CEO of Sosei Heptares, added: “We are delighted to enter this collaboration and license agreement with Biohaven for our portfolio of novel CGRP receptor antagonists. 

“HTL0022562 has already advanced successfully through a rigorous preclinical program and we are confident that the CGRP expertise and resources Biohaven brings will enable the further development of this and other promising CGRP antagonist candidates into human clinical trials. 

“This new agreement is an excellent example of our strategy in action, which is focused on achieving sustainable profitability through drug discovery, early development and partnering. 

“It showcases our ability to advance strategically important candidates against specific disease targets through early development to become attractive partnering opportunities in parallel with the multi-target deals we have established.”

Newsletter Subscription

Stay informed of the latest news and features